ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.05
-0.10 (-1.40%)
As of 10:26AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.15
Open7.19
Bid7.02 x 1100
Ask7.03 x 2200
Day's Range6.97 - 7.19
52 Week Range5.42 - 18.50
Volume413,048
Avg. Volume3,113,283
Market Cap1.582B
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateMay 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.17
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    Endo to Announce First-Quarter 2019 Financial Results

    DUBLIN , April 10, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its first-quarter 2019 financial results on May 9, 2019 and members of its senior management team will host a ...

  • When Will Endo International plc (NASDAQ:ENDP) Breakeven?
    Simply Wall St.14 days ago

    When Will Endo International plc (NASDAQ:ENDP) Breakeven?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Endo International plc's (NASDAQ:ENDP): Endo International plc manufactures and sells generic and branded pharmaceutica...

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding ENDP is favorable, with net inflows of $294.35 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire18 days ago

    Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States

    DUBLIN , April 5, 2019 /PRNewswire/ --   Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version ...

  • Drug companies that benefit from the war on opioid addiction
    Yahoo Finance22 days ago

    Drug companies that benefit from the war on opioid addiction

    The opioid crisis in the United States is a medical and societal tragedy, but some companies are working to fight addiction.

  • Why Is Endo (ENDP) Down 26.9% Since Last Earnings Report?
    Zacks24 days ago

    Why Is Endo (ENDP) Down 26.9% Since Last Earnings Report?

    Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire27 days ago

    Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes

    DUBLIN, March 27, 2019 /PRNewswire/ -- Endo International plc (ENDP) (the "Company" or "Endo")  today announced the early tender results of the previously announced cash tender offers (the "Tender Offers") made by Endo Finance LLC ("Endo Finance"), a wholly-owned subsidiary of Endo International plc, for the debt securities listed in the table below (collectively, the "Notes" and each a "series"). The aggregate principal amount of each series of Notes that were validly tendered and not validly withdrawn as of 5:00 p.m., New York City time, on March 27, 2019  (the "Early Tender Date"), as reported by the tender agent, are specified in the table below.

  • Endo International: Wall Street Ratings Not Very Favorable?
    Market Realist29 days ago

    Endo International: Wall Street Ratings Not Very Favorable?

    How Generic Pharmaceutical Stocks Are Positioned this Month(Continued from Prior Part)Analysts’ recommendations and target prices Wall Street analysts expect an upside potential of 70.11% for Endo International (ENDP), based on the company’s

  • Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
    Zackslast month

    Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

    Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

  • PR Newswirelast month

    Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery

    Leading Peer-Reviewed Dermatology Journal Features Phase 2 Data DUBLIN , March 19, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the publication of Phase 2 data evaluating ...

  • BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
    Zackslast month

    BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

    BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

  • PR Newswirelast month

    Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) today announced an upsizing of its previously announced cash tender offers (the "Tender Offers") and consent solicitations by Endo Finance LLC ("Endo Finance"), a wholly-owned subsidiary of Endo International plc. Endo Finance amended the Tender Offers to increase (i) the Aggregate Purchase Price (as defined below) from the initial amount of $1.0 billion to $1.5 billion for all of the Notes (as defined below) validly tendered and not validly withdrawn in the Tender Offers and (ii) the Acceptance Sublimit (as defined below) from the initial aggregate amount of $500.0 million to $650.0 million. All other terms of the Tender Offers and the related consent solicitations, as previously announced, remain unchanged.

  • PR Newswirelast month

    Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, priced $1.5 billion aggregate principal amount of 7.500% senior secured notes due 2027 at an issue price of $1,000 per $1,000 principal amount in connection with its previously announced private offering, which represents an upsize of $500.0 million over the previously contemplated offering amount. The notes will be senior secured obligations of the Issuer and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its existing senior secured credit facilities and existing senior secured notes. Endo intends to use the net proceeds from the offering, together with cash on hand, to fund cash tender offers (the "Tender Offers") by Endo Finance LLC, a wholly-owned subsidiary of Endo, to purchase a portion of Endo's outstanding senior unsecured notes and to pay certain related premiums, fees and expenses.

  • Moody'slast month

    Endo Finance Co. -- Moody's downgrades Endo's secured debt to Ba3, unsecured notes to Caa1; B2 CFR affirmed

    Moody's Investors Service ("Moody's") downgraded the senior secured ratings of Endo Luxembourg Finance I Company S.à.r.l. Moody's also assigned a Ba3 rating to the proposed secured revolving credit facility and to the proposed secured notes being issued by Par Pharmaceuticals, Inc., a subsidiary of Endo. The notes will have the same upstream and downstream guarantees as Endo's other secured debt.

  • Insys Plunges on Auditor's Concern About Insufficient Funds
    Zackslast month

    Insys Plunges on Auditor's Concern About Insufficient Funds

    Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

  • PR Newswirelast month

    Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) today announced a series of debt refinancing transactions that are intended to help manage the debt maturity profile of it and certain of its subsidiaries (collectively, the "Company" or "Endo").

  • PR Newswirelast month

    Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

    DUBLIN, March 14, 2019 /PRNewswire/ -- Endo International plc (ENDP) ("Endo") today announced that Par Pharmaceutical, Inc. (the "Issuer"), its wholly-owned subsidiary, intends to offer senior secured notes, subject to market and customary conditions. The notes will be senior secured obligations of the Issuer and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its existing senior secured credit facilities and existing senior secured notes. Endo intends to use the net proceeds from the proposed offering, together with cash on hand, to fund cash tender offers (the "Tender Offers") by Endo Finance LLC, a wholly-owned subsidiary of Endo, to purchase a portion of Endo's outstanding senior unsecured notes and to pay certain related premiums, fees and expenses.

  • Is Endo International (ENDP) a Great Stock for Value Investors?
    Zackslast month

    Is Endo International (ENDP) a Great Stock for Value Investors?

    Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

  • Reuterslast month

    Opioid litigation concerns weigh on pharmaceutical loan borrowers

    The opioid crisis came to the loan market last week, as the potential fallout from lawsuits weighed on manufacturers of the drugs cited as a root cause of the epidemic. Pharmaceutical company Endo International’s US$3.4bn term loan was quoted at 97.75-98.5 on Monday, unchanged from Friday but down from 99.625-100.125 on March 4, as its stock fell 23% during the same five-day period. The drop followed a Reuters report that fellow drug producer Purdue Pharma, the maker of OxyContin, was exploring bankruptcy to address liabilities stemming from lawsuits tied to the opioid crisis.

  • What’s Expected to Drive Endo’s Growth in Fiscal 2019?
    Market Realistlast month

    What’s Expected to Drive Endo’s Growth in Fiscal 2019?

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Financial performanceIn fiscal 2018, Endo International’s (ENDP) revenue fell 15.04% YoY (year-over-year) to $2.95 billion but beat its guidance of $2.87

  • Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts
    Market Realistlast month

    Comparing Endo’s and Mallinckrodt’s Gross Margin Forecasts

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Gross margin comparison In its fourth-quarter conference call, Endo International (ENDP) guided for its gross margin contracting YoY (year-over-year) in fiscal 2019

  • How Endo’s and Mallinckrodt’s Expense Control Stacks Up
    Market Realistlast month

    How Endo’s and Mallinckrodt’s Expense Control Stacks Up

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for its fiscal 2019 adjusted operating expenses as a

  • Endo International’s and Mallinckrodt’s EPS Growth Expectations
    Market Realist2 months ago

    Endo International’s and Mallinckrodt’s EPS Growth Expectations

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Earnings guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for adjusted diluted EPS and adjusted EBITDA of

  • Comparing Endo’s and Mallinckrodt’s Revenue Forecasts
    Market Realist2 months ago

    Comparing Endo’s and Mallinckrodt’s Revenue Forecasts

    Comparing Generic Pharma Stocks: Endo versus Mallinckrodt(Continued from Prior Part)Revenue guidance for fiscal 2019 In its fourth-quarter investor presentation, Endo International (ENDP) guided for fiscal 2019 revenue of $2.76 billion–$2.96